AP NEWS

Global Diabetic Nephropathy Market Outlook to 2022 with AstraZeneca, Merck and Sanofi Dominating - ResearchAndMarkets.com

January 8, 2019

DUBLIN--(BUSINESS WIRE)--Jan 8, 2019--The “Global Diabetic Nephropathy Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The diabetic nephropathy market will register a CAGR of almost 34% by 2022.

Rise in incidence of diabetes to push growth in the market

Globally, there has been a rise in the incidence and prevalence of diabetes, which has resulted in the occurrence of chronic kidney disease in patients.

Increasing incidence of diabetic nephropathy among diabetic patients

The incidence of diabetic nephropathy was observed to be much higher in freshly diagnosed cases of type 2 diabetes patients. The factors associated with the rise of incidence of nephropathy are hypertension, hypercholesterolemia, and obesity.

Growing economic burden of diabetic nephropathy

Diabetic nephropathy is a complication associated with diabetes mellitus. The cost associated with diabetic nephropathy increases gradually with the progression of disease due to the associated cost drivers such as dialysis and hospitalization.

Key Players

AstraZeneca Merck Sanofi

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

Market definition Market sizing 2017 Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY DRUG CLASS

Segmentation by drug class Comparison by drug class ARBs - Market size and forecast 2017-2022 ACE inhibitors - Market size and forecast 2017-2022 Others - Market size and forecast 2017-2022 Market opportunity by drug class

PART 09: MARKET SEGMENTATION BY TYPE OF DISEASE

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Americas - Market size and forecast 2017-2022 EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

Rise in incidence of diabetes Increase in diabetic nephropathy-related cardiovascular mortality and end-stage renal disease Multidisciplinary approach for the management of diabetic nephropathy

PART 15: VENDOR LANDSCAPE

Overview Landscape disruption

PART 16: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors AstraZeneca Merck Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/7ccgpp/global_diabetic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190108005612/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs,Endocrine and Metabolic Disorders Drugs,Urology and Nephrology

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/08/2019 08:43 AM/DISC: 01/08/2019 08:43 AM

http://www.businesswire.com/news/home/20190108005612/en

AP RADIO
Update hourly